Skip to main content

AMYVID ALIGNS WITH THE SCHEDULING OF YOUR PATIENTS AND IMAGING CENTERS

Minimal patient preparation required prior to scan1,2

Blue checkmark icon

No contraindications

Blue checkmark icon

No glucose monitoring or fasting required

Blue clock icon

Total procedure time ~40 to 60 minutes from tracer injection to scan completion1

Blue person icon

Injection followed by 30- to 50-minute uptake

Blue PET scan icon

10-minute PET scan

With a contrast window that lasts up to 60 minutes after 30-minute uptake, Amyvid provides flexibility for scheduling and technical delays, and even offers opportunity for a repeat scan, if necessary.1

Amyloid PET tracers: uptake and scan times1,3,4

Amyvid dosing and procedure

TRACER
UPTAKE
SCAN TIME
TOTAL ESTIMATED TIME
TRACER Amyvid®
(florbetapir F 18 injection) 		UPTAKE 30-50
minutes 		SCAN TIME 10
minutes 		TOTAL ESTIMATED TIME 40-60
minutes
TRACER Neuraceq®
(florbetaben F 18 injection) 		UPTAKE 45-130
minutes 		SCAN TIME 15-20
minutes 		TOTAL ESTIMATED TIME 60-150
minutes
TRACER Vizamyl™
(flutemetamol F 18 injection) 		UPTAKE 60-120
minutes 		SCAN TIME 10-20
minutes 		TOTAL ESTIMATED TIME 70-140
minutes
  • This is a comparison of the uptake and scan times of currently FDA-approved amyloid PET tracers and is NOT a comparison of efficacy and safety
  • Neuraceq® is a registered trademark of Life Molecular Imaging Ltd. in the EU, US and other countries.
  • Vizamyl™ is a trademark of General Electric Company or one of its subsidiaries

Amyvid dosing and administration

The recommended dose for Amyvid is 370 MBq (10 mCi), maximum 50 μg mass dose, administered as a single intravenous (IV) bolus in a total volume of 10 mL or less. Follow the injection with an IV flush of 0.9% sterile sodium chloride.1

  • Inspect the radiopharmaceutical dose solution prior to administration and do not use if it contains particulate matter or is discolored
  • Use aseptic technique and radiation shielding to withdraw Amyvid solution
  • Assay the dose in a suitable dose calibrator prior to administration
  • Inject Amyvid through a short IV catheter (approximately 1.5 inches or less) to minimize the potential for adsorption of the drug to the catheter. Portions of the Amyvid dose may adhere to longer catheters

Radiation Safety - Drug Handling

Amyvid is a radioactive drug and should be handled with appropriate safety measures to minimize radiation exposure during administration. Use waterproof gloves and effective shielding, including syringe shields when handling Amyvid. Radiopharmaceuticals, including Amyvid, should only be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radioactive materials, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.

SELECT IMPORTANT SAFETY INFORMATION:

Risk for Image Misinterpretation and Other Errors

  • Errors may occur in the Amyvid estimation of brain neuritic plaque density during image interpretation
  • Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to errors. Other errors may be due to extensive brain atrophy that limits the ability to distinguish gray and white matter on the Amyvid scan as well as motion artifacts that distort the image
  • Amyvid scan results are indicative of the brain neuritic amyloid plaque content only at the time of image acquisition and a negative scan result does not preclude the development of brain amyloid in the future

PET=positron emission tomography.

Learn how Amyvid can support you and your patients

AMYVID SUPPORT Right

REFERENCES

  1. Amyvid (florbetapir F 18 injection) Prescribing Information. Lilly USA, LLC.
  2. Trembath L, Newell M, Devous MD Sr. Technical considerations in brain amyloid PET imaging with 18F-florbetapir. J Nucl Med Technol. 2015;43(3):175-184.
  3. Neuraceq [Prescribing Information]. Matran, Switzerland: Life Molecular Imaging, S.A.
  4. Vizamyl [Prescribing Information]. Arlington Heights, IL: GE Healthcare.

Important Safety Information

Risk for Image Misinterpretation and Other Errors
  • Errors may occur in the Amyvid estimation of brain neuritic plaque density during image interpretation
  • Image interpretation should be performed independently of the patient’s clinical information. The use of clinical information in the interpretation of Amyvid images has not been evaluated and may lead to errors. Other errors may be due to extensive brain atrophy that limits the ability to distinguish gray and white matter on the Amyvid scan as well as motion artifacts that distort the image
  • Amyvid scan results are indicative of the brain neuritic amyloid plaque content only at the time of image acquisition and a negative scan result does not preclude the development of brain amyloid in the future

Radiation Risk

  • Amyvid, similar to other radiopharmaceuticals, contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure

The most common adverse reactions reported in clinical trials were headache (1.8%), musculoskeletal pain (0.7%), blood pressure increased (0.7%), nausea (0.7%), fatigue (0.5%), and injection site reaction (0.5%)

Please see Full Prescribing Information for Amyvid.

AM HCP ISI 14SEP2022

Indication

Amyvid is a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.

A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.

Amyvid for intravenous use is supplied in multidose vials containing 500-1900 MBq/mL Florbetapir F 18.

Limitations of Use:

  • A positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder
  • Safety and effectiveness of Amyvid have not been established for:
    • Predicting development of dementia or other neurologic condition
    • Monitoring responses to therapies